No standing medical-countermeasures stockpile and surge-manufacturing strategy

The £1bn Pandemic Preparedness Strategy (2025) funds PPE replenishment, some UK vaccine capacity (Moderna, Harwell) and testing-chemical stockpiles. But CLTR notes the plan lacks a comprehensive strategy to boost supply-chain resilience for medical countermeasures and offers no detailed reshoring analysis. There is no standing surge-manufacturing 'warm base' (a UK equivalent of a permanent BARDA-style capacity) nor a published cross-hazard national stockpile strategy with maintained, rotated reserves.

In 2020 the UK was exposed by global scrambles for PPE, reagents and vaccines. Ad hoc stockpiles degrade and surge manufacturing cannot be improvised; a warm-base capability is the difference between 100-day and 12-month countermeasure availability.

A published national stockpile strategy (rotated, cross-hazard reserves) plus funded warm-base surge-manufacturing capacity and reshoring of critical medical inputs, explicitly tied to the 100 Days Mission.

// State-led: Instrument: government stockpile strategy plus DHSC-funded BARDA-style warm-base manufacturing; spending-review decisions outsiders cannot ship.

Warm-base surge manufacturing decides 100-day versus 12-month countermeasures, but the £1bn strategy already funds adjacent stockpiles and no dated trigger forces the reshoring piece now.